<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37200039</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5783</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Investigative ophthalmology &amp; visual science</Title><ISOAbbreviation>Invest Ophthalmol Vis Sci</ISOAbbreviation></Journal><ArticleTitle>Myofiber Type Shift in Extraocular Muscles in Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>15</StartPage><MedlinePgn>15</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">15</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1167/iovs.64.5.15</ELocationID><Abstract><AbstractText Label="PURPOSE">To investigate changes in myofiber composition in the global layer (GL) and orbital layer (OL) of extraocular muscles (EOMs) from terminal amyotrophic lateral sclerosis (ALS) donors.</AbstractText><AbstractText Label="METHODS">Medial recti muscles collected postmortem from spinal-onset ALS, bulbar-onset ALS, and healthy control donors were processed for immunofluorescence with antibodies against myosin heavy chain (MyHC) IIa, MyHCI, MyHCeom, laminin, neurofilaments, synaptophysin, acetylcholine receptor &#x3b3;-subunit, and &#x3b1;-bungarotoxin.</AbstractText><AbstractText Label="RESULTS">The proportion of myofibers containing MyHCIIa was significantly smaller and MyHCeom was significantly larger in the GL of spinal-onset ALS and bulbar-onset ALS donors compared to control donors. Changes in the GL were more prominent in the bulbar-onset ALS donors, with a significantly larger proportion of myofibers containing MyHCeom being present compared to spinal-onset ALS donors. There were no significant differences in the myofiber composition in the OL. In the spinal-onset ALS donors, the proportions of myofibers containing MyHCIIa in the GL and MyHCeom in the OL were significantly correlated with the disease duration. Neurofilament and synaptophysin were present at motor endplates of myofibers containing MyHCeom in ALS donors.</AbstractText><AbstractText Label="CONCLUSIONS">The EOMs of terminal ALS donors displayed changes in the fast-type myofiber composition in the GL, with a more pronounced alteration in bulbar-onset ALS donors. Our results align with the worse prognosis and subclinical changes in eye movement function previously observed in bulbar-onset ALS patients and suggest that the myofibers in the OL might be more resistant to the pathological process in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Behzadi</LastName><ForeName>Arvin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Neurosciences, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Integrative Medical Biology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>https://orcid.org/0000-0002-9347-0364.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tjust</LastName><ForeName>Anton Erik</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Neurosciences, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Integrative Medical Biology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>https://orcid.org/0000-0003-2369-4319.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jing-Xia</ForeName><Initials>JX</Initials><AffiliationInfo><Affiliation>Department of Integrative Medical Biology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>https://orcid.org/0000-0003-2508-9921.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter Munch</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Neurosciences, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>https://orcid.org/0000-0003-0094-5429.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Br&#xe4;nnstr&#xf6;m</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Biosciences, Pathology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>https://orcid.org/0000-0002-4201-8204.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedrosa Domell&#xf6;f</LastName><ForeName>Fatima</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Integrative Medical Biology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences, Ophtalmology, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>https://orcid.org/0000-0002-0648-4996.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA><NlmUniqueID>7703701</NlmUniqueID><ISSNLinking>0146-0404</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016708">Synaptophysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.1</RegistryNumber><NameOfSubstance UI="D018995">Myosin Heavy Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009801" MajorTopicYN="Y">Oculomotor Muscles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016708" MajorTopicYN="N">Synaptophysin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018995" MajorTopicYN="N">Myosin Heavy Chains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure: <b>A. Behzadi</b>, Pharma Industry Publishing AB (F); <b>A.E. Tjust</b>, None; <b>J.-X. Liu</b>, None; <b>P.M. Andersen</b>, Biogen (C, F), Orphazyme (C, F), Roche (C, F), Regeneron (C, F), Avrion (C, F), uniQure (C, F), AL-S Pharma (C, F), Sanofi (C, F), Amylyx (C, F), Alexion (C, F), Orion Pharma (C, F), Eli Lilly (C, F), PTC Pharmaceuticals (C, F); <b>T. Br&#xe4;nnstr&#xf6;m</b>, None; <b>F. Pedrosa Domell&#xf6;f</b>, None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>18</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>18</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37200039</ArticleId><ArticleId IdType="pmc">PMC10207955</ArticleId><ArticleId IdType="doi">10.1167/iovs.64.5.15</ArticleId><ArticleId IdType="pii">2785628</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zarei S, Carr K, Reiley L, et al. .. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015; 6: 171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W.. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014; 10: 661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Hardiman O, et al. .. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009; 10: 310&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Su W-M, Cheng Y-F, Jiang Z, et al. .. Predictors of survival in patients with amyotrophic lateral sclerosis: a large meta-analysis. eBioMedicine. 2021; 74: 103732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646173</ArticleId><ArticleId IdType="pubmed">34864363</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, Debray TPA, Visser AE, et al. .. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018; 17: 423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Behzadi A, Pujol-Calder&#xf3;n F, Tjust AE, et al. .. Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics. Sci Rep. 2021; 11: 22128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8585882</ArticleId><ArticleId IdType="pubmed">34764380</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP.. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017; 88: 540&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk AE, Weishaupt JH, Andersen PM, Ludolph AC, Kubisch C.. Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Med Genet. 2018; 30: 252&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132774</ArticleId><ArticleId IdType="pubmed">30220791</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen B, Caroscio J.. Eye movements in amyotrophic lateral sclerosis. J Neural Transm Suppl. 1983; 19: 305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">6583314</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani T, Aki M, Shiozawa R, et al. .. Development of ophthalmoplegia in amyotrophic lateral sclerosis during long-term use of respirators. J Neurol Sci. 1990; 99: 311&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">2086731</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani T, Sakamaki S, Tsuchiya N, et al. .. Amyotrophic lateral sclerosis with ophthalmoplegia and multisystem degeneration in patients on long-term use of respirators. Acta Neuropathol. 1992; 84: 372&#x2013;377.</Citation><ArticleIdList><ArticleId IdType="pubmed">1441918</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallestad KM, Hebert SL, McDonald AA, Daniel ML, Cu SR, McLoon LK.. Sparing of extraocular muscle in aging and muscular dystrophies: a myogenic precursor cell hypothesis. Exp Cell Res. 2011; 317: 873&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072110</ArticleId><ArticleId IdType="pubmed">21277300</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer RF, Porter JD.. Biological organization of the extraocular muscles. Prog Brain Res. 2006; 151: 43&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">16221585</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer MD, Gorospe JR, Felder E, et al. .. Expression profiling reveals metabolic and structural components of extraocular muscles. Physiol Genomics. 2002; 9: 71&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">12006673</ArticleId></ArticleIdList></Reference><Reference><Citation>McLoon LK, Park HN, Kim JH, Pedrosa-Domell&#xf6;f F, Thompson LV.. A continuum of myofibers in adult rabbit extraocular muscle: force, shortening velocity, and patterns of myosin heavy chain colocalization. J Appl Physiol (1985). 2011; 111: 1178&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191789</ArticleId><ArticleId IdType="pubmed">21778415</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjellgren D, Thornell LE, Andersen J, Pedrosa-Domell&#xf6;f F.. Myosin heavy chain isoforms in human extraocular muscles. Invest Ophthalmol Vis Sci. 2003; 44: 1419&#x2013;1425.</Citation><ArticleIdList><ArticleId IdType="pubmed">12657575</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi M, Liu JX, Br&#xe4;nnstr&#xf6;m T, Andersen PM, St&#xe5;l P, Pedrosa-Domell&#xf6;f F.. Human extraocular muscles in ALS. Invest Ophthalmol Vis Sci. 2010; 51: 3494&#x2013;3501.</Citation><ArticleIdList><ArticleId IdType="pubmed">20181843</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjust AE, Brannstrom T, Pedrosa Domellof F. Unaffected motor endplate occupancy in eye muscles of ALS G93A mouse model. Front Biosci (Schol Ed). 2012; 4: 1547&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pubmed">22652891</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JX, Br&#xe4;nnstr&#xf6;m T, Andersen PM, Pedrosa-Domell&#xf6;f F.. Distinct changes in synaptic protein composition at neuromuscular junctions of extraocular muscles versus limb muscles of ALS donors. PLoS One. 2013; 8: e57473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3582511</ArticleId><ArticleId IdType="pubmed">23468993</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjust AE, Danielsson A, Andersen PM, Br&#xe4;nnstr&#xf6;m T, Pedrosa Domell&#xf6;f F. Impact of amyotrophic lateral sclerosis on slow tonic myofiber composition in human extraocular muscles. Invest Ophthalmol Vis Sci. 2017; 58: 3708&#x2013;3715.</Citation><ArticleIdList><ArticleId IdType="pubmed">28738414</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberhorn AC, Ardeleanu P, B&#xfc;ttner-Ennever JA, Horn AKE.. Histochemical differences between motoneurons supplying multiply and singly innervated extraocular muscle fibers. J Comp Neurol. 2005; 491: 352&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">16175553</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Borasio GD, Dengler R, et al. .. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol. 2005; 12: 921&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pubmed">16324086</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JX, Domell&#xf6;f FP.. A novel type of multiterminal motor endplate in human extraocular muscles. Invest Ophthalmol Vis Sci. 2018; 59: 539&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">29372252</ArticleId></ArticleIdList></Reference><Reference><Citation>Gundersen HJ, Bendtsen TF, Korbo L, et al. .. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS. 1988; 96: 379&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">3288247</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaghy C, Pinnock R, Abrahams S, et al. .. Slow saccades in bulbar-onset motor neurone disease. J Neurol. 2010; 257: 1134&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pubmed">20146069</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang BH, Kim JI, Lim YM, Kim KK.. Abnormal oculomotor functions in amyotrophic lateral sclerosis. J Clin Neurol. 2018; 14: 464&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6172508</ArticleId><ArticleId IdType="pubmed">30198218</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter JD, Baker RS, Ragusa RJ, Brueckner JK.. Extraocular muscles: basic and clinical aspects of structure and function. Surv Ophthalmol. 1995; 39: 451&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">7660301</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjellgren D, Thornell LE, Virtanen I, Pedrosa-Domell&#xf6;f F.. Laminin isoforms in human extraocular muscles. Invest Ophthalmol Vis Sci. 2004; 45: 4233&#x2013;4239.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557425</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumer R, Streicher J, Carrero-Rojas G, Calvo PM, de la Cruz RR, Pastor AM.. Palisade endings have an exocytotic machinery but lack acetylcholine receptors and distinct acetylcholinesterase activity. Invest Ophthalmol Vis Sci. 2020; 61: 31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7774060</ArticleId><ArticleId IdType="pubmed">33369640</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockington A, Ning K, Heath PR, et al. .. Unravelling the enigma of selective vulnerability in neurodegeneration: motor neurons resistant to degeneration in ALS show distinct gene expression characteristics and decreased susceptibility to excitotoxicity. Acta Neuropathol. 2012; 125: 95&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535376</ArticleId><ArticleId IdType="pubmed">23143228</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>